Oncotarget

Meta-Analysis:

Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis

Stephanie Tuminello, Rajwanth Veluswamy, Wil Lieberman-Cribbin, Sacha Gnjatic, Francesca Petralia, Pei Wang, Raja Flores and Emanuela Taioli _

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2019; 10:7142-7155. https://doi.org/10.18632/oncotarget.27392

Metrics: PDF 1707 views  |   Full Text 2864 views  |   ?  


Abstract

Stephanie Tuminello1, Rajwanth Veluswamy1,2, Wil Lieberman-Cribbin1, Sacha Gnjatic2,3,4, Francesca Petralia5, Pei Wang5, Raja Flores6 and Emanuela Taioli1,6,7

1 Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA

2 Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

3 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

4 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

5 Department of Genetics and Genomic Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA

6 Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA

7 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Correspondence to:

Emanuela Taioli,email: [email protected]

Keywords: NSCLC; immune contexture; tumor microenvironment; TILs

Received: September 18, 2019     Accepted: December 05, 2019     Published: December 24, 2019

ABSTRACT

Background: Early-stage non-small cell lung cancer (NSCLC) patients carry significant risk of recurrence post-surgery. In-depth characterization of the immune tumor microenvironment (TME) can have prognostic value. This study aimed to evaluate the association of individual immune cell types in the TME with clinical outcomes in surgically resected, early-stage NSCLC.

Methods: We performed a systematic literature search of the National Library of Medicine database through November 2019, investigating predefined biomarkers (CD3+ T cells, CD4+ T helper cells, CD8+ cytotoxic T cells, CD20+ B cells, CD56+ & CD57+ Natural Killer (NK) cells, CD68+ Tissue Associated Macrophages (TAMS), FoxP3+ T regulatory cells, and Mast Cells (MC)), and their association with survival following PRISMA guidelines.

Results: Studies that adjusted for important clinical covariates (such as stage and age) showed that higher levels of CD8+ cytotoxic T cells were associated with improved OS (HR = 0.68; 95% CI, 0.50–0.93) and DFS (HR = 0.60; 95% CI, 0.41–0.87), while increased CD20+ B cells (HR = 0.16; 95% CI, 0.04–0.64) and CD 56/57+ NK cells (HR = 0.50; 95% CI, 0.26–0.95) were associated with improved OS; lung cancers with increased FoxP3+ T regulatory cells (HR = 2.22; 95% CI, 1.47–3.34) had worse OS.

Conclusions: Immune cell components of the TME have prognostic value in early-stage, surgically resected NSCLC, and may reveal which patients are more likely to need additional systemic treatment, including immunotherapy. Clinical covariates need to be considered when evaluating the prognostic value of immune cells in the TME.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27392